In prostate cancer, this protein is overexpressed by 100 to 1000 times, correlating with tumour aggressiveness, which has been successfully utilised in nuclear imaging by employing [68Ga]Ga-labelled or [18F]F-labelled PSMA as a PET radiotracer for detecting prostate cancer lesions [7]. Here, FOLH1 is linked to prostate carcinoma.